Zynerba says target blood levels in ZYN001 THC-Prodrug patch study not achieved
Zynerba Pharmaceuticals (ZYNE) announced top line results from a Phase 1 clinical program studying ZYN001, the Company’s patent-protected, pro-drug of tetrahydrocannabinol delivered via a transdermal patch, in healthy volunteers.
The program assessed the safety and pharmacokinetics in single and multiple doses of several formulations of ZYN001.
The top line results of this Phase 1 study indicate that target blood levels of 5 to 15 ng/ml THC were not achieved.
ZYN001 was very well tolerated with minimal skin erythema.
There were no serious adverse events or discontinuations for subjects receiving ZYN001.
As a result of these data, the Company will focus its development efforts and investments on the ZYN002 Fragile X syndrome, developmental and epileptic encephalopathy and adult refractory epilepsy programs.
The company expects that this change will extend its cash runway into the second half of 2019.
This Phase 1 study was a single and multiple dose, placebo-controlled first-in-man study to assess the safety and pharmacokinetics of ZYN001 administered as a transdermal patch to healthy adult subjects.
Several formulations and patch wear times ranging from 24 hours to 14 days were assessed in in 60 healthy subjects who were randomized to ZYN001 or placebo.
ZYNE closed at $9.61, it last traded at $7.60.
To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners.
This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.